Cardiovascular Disease Risk Factors in HIV-1 Patients on HAART
Author Information
Author(s): Domingo Pere, Suarez-Lozano Ignacio, Teira Ramón, Lozano Fernando, Terrón Alberto, Viciana Pompeyo, González Juan, Galindo Mª José, Geijo Paloma, Vergara Antonio, Cosín Jaime, Ribera Esteban, Roca Bernardino, Garcia-Alcalde Mª Luisa, Sánchez Trinitario, Torres Ferran, Lacalle Juan Ramón, Garrido Myriam
Primary Institution: Hospital de la Santa Creu i Sant Pau
Hypothesis
What is the prevalence of cardiovascular disease risk factors among HIV-1-infected individuals treated with HAART?
Conclusion
HIV-1 patients in the VACH cohort have multiple cardiovascular disease risk factors and low usage of lipid-lowering therapy.
Supporting Evidence
- More than 18% of the study population was at an age of appreciable risk of CVD.
- 1.7% had previous CVD and 59.2% were smokers.
- NNRTI and/or PI-based therapies were associated with the worst lipid profiles.
- Only 11.3% to 26.8% of patients needing lipid-lowering therapy were treated.
- Elevated total cholesterol was significantly associated with higher CD4 counts.
Takeaway
People with HIV who take certain medications have a higher chance of heart problems, but not many are getting the help they need to lower their cholesterol.
Methodology
Multicentric, cross-sectional analysis of cardiovascular disease risk factors in treated patients from the VACH cohort.
Potential Biases
Observational design limits causal conclusions and may introduce measurement inconsistencies.
Limitations
The study may not be representative of the broader HIV-1-infected population due to its specific demographic and geographic focus.
Participant Demographics
Patients aged 18 and above, with documented HIV-1 infection, attending outpatient treatment centers.
Statistical Information
P-Value
0.005
Confidence Interval
95% CI: 1.16-1.47 per log2CD4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website